| Cas No.: | 2306178-56-1 |
| Chemical Name: | 5-[4-(2-Methoxyethoxy)phenyl]-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one |
| Synonyms: | DMX 5084 pound>>DMX5084;BCP30841;5-(4-(2-Methoxyethoxy)phenyl)-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one;5-[4-(2-Methoxyethoxy)phenyl]-7-phenyl-3H-pyrrolo[2,3-d]pyrimidin-4-one;DMX-5804 |
| SMILES: | O(C([H])([H])C([H])([H])OC([H])([H])[H])C1C([H])=C([H])C(=C([H])C=1[H])C1=C([H])N(C2C([H])=C([H])C([H])=C([H])C=2[H])C2=C1C(N([H])C([H])=N2)=O |
| Formula: | C21H19N3O3 |
| M.Wt: | 361.3939 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | DMX-5804 is a potent, orally active and selective MAP4K4 inhibitor, with an IC50 of 3 nM, a pIC50 of 8.55 for human MAP4K4, less potent on MINK1/MAP4K6 (pIC50, 8.18), and TNIK/MAP4K7 (pIC50, 7.96). DMX-5804 enhances cardiomyocyte survival, and reduces ischemia-reperfusion injury in mice[1]. |
| In Vitro: | DMX-5804 exhibits great selectivity at MAP4K4 over other kinases, such as GCK/MAP4K2 (pIC50, 6.50), GLK/MAP4K3 (pIC50, 4.95), KHS/MAP4K5 (pIC50, 6.36), ABL1 (pIC50, 5.80), Aurora B (pIC50, 5.49), FLT3 (pIC50, 5.31), GSK3β (pIC50, 4.66), MLK1/MAP3K9 (pIC50, 7.19), MLK3/MAP3K11 (pIC50, 6.99), NUAK (pIC50, 6.88) and VEGFR (pIC50, 5.72)[1]. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|